Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShORe phase 3 trial of intravitreal OPT-302 plus ranibizumab versus ranibizumab alone in neovascular age-related macular degeneration
MOH_2021-08-26_010226Phase 3Not yet recruiting
- Sponsor
- Opthea Limited
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept and ranibizumab in exudative macular degeneration (3 arms), sponsored by Opthea Limited. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
soziniberceptranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-08-26_010226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-26_010226.